当前位置: X-MOL 学术ACS Med. Chem. Lett. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors
ACS Medicinal Chemistry Letters ( IF 3.5 ) Pub Date : 2018-07-13 00:00:00 , DOI: 10.1021/acsmedchemlett.8b00200
Bernard Barlaam 1 , Elaine Cadogan 1 , Andrew Campbell 2 , Nicola Colclough 1 , Allan Dishington 2 , Stephen Durant 1 , Kristin Goldberg 1 , Lorraine A. Hassall 2 , Gareth D. Hughes 1 , Philip A. MacFaul 2 , Thomas M. McGuire 1 , Martin Pass 1 , Anil Patel 2 , Stuart Pearson 1 , Jens Petersen 3 , Kurt G. Pike 1 , Graeme Robb 1 , Natalie Stratton 4 , Guohong Xin 5 , Baochang Zhai 5
Affiliation  

We report the discovery of a novel series of 3-cinnoline carboxamides as highly potent and selective ataxia telangiectasia mutated (ATM) kinase inhibitors. Optimization of this series focusing on potency and physicochemical properties (especially permeability) led to the identification of compound 21, a highly potent ATM inhibitor (ATM cell IC50 0.0028 μM) with excellent kinase selectivity and favorable physicochemical and pharmacokinetics properties. In vivo, 21 in combination with irinotecan showed tumor regression in the SW620 colorectal tumor xenograft model, superior inhibition to irinotecan alone. Compound 21 was selected for preclinical evaluation alongside AZD0156.

中文翻译:

一系列3-Cinnoline羧酰胺的发现,它们是口服生物可利用的,高度有效的和选择性的ATM抑制剂

我们报告发现的新型3-cinnoline羧酰胺系列作为高效和选择性共济失调毛细血管扩张(ATM)激酶抑制剂。通过优化该系列药物的效价和理化性质(尤其是渗透性),可以鉴定出化合物21,这是一种高效的ATM抑制剂(ATM cell IC 50 0.0028μM),具有出色的激酶选择性以及良好的理化和药代动力学特性。在体内21与伊立替康的组合在SW620大肠肿瘤异种移植模型中显示出肿瘤消退,其抑制作用优于单独的伊立替康。选择了化合物21和AZD0156进行临床前评估。
更新日期:2018-07-13
down
wechat
bug